TipRanksMAR 304 min read$INM

InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance

InMed Pharmaceuticals (INM) has received a Nasdaq notification for noncompliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive days. The company has 180 days to regain compliance, with a possible 180-day extension, to avoid delisting. An analyst rates INM as a Hold with a $0.64 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial performance and a bearish technical trend.

Original reporting

TipRanks · TipRanks Auto-Generated Newsdesk

Published Mar 30, 2026, 11:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Mar 30, 2026, 11:30 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance — source image — Source · TipRanks

Decision brief

The 30-second read

$INMBearishLow

Why it matters

Noncompliance could lead to delisting, affecting liquidity and investor confidence. The company's management may undertake measures to restore compliance, influencing stock performance.

Market read

The issue is highly relevant for traders holding or considering positions in INM, with potential for increased volatility.

What to watch

Possible positive developments such as partnership announcements or clinical trial progress could offset negative sentiment.

Timing: short-term (next 1-3 months)

Background

InMed Pharmaceuticals is a biotech firm focused on developing cannabinoid-based therapies. Nasdaq requires a minimum bid price of $1.00 to maintain listing status.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INMBearishMedium confidence

Context

The news pertains directly to InMed Pharmaceuticals (INM), a biotech company facing Nasdaq minimum bid price noncompliance.

Expected impact

Potential short-term decline due to noncompliance concerns; possible rebound if compliance is restored or if positive developments occur.

Evidence & confidence

The noncompliance introduces uncertainty and potential delisting risk, which typically exerts downward pressure on the stock. However, the company's ability to regain compliance within the extension period could mitigate long-term negative impacts.

Market effects

Sector

The biotech sector may experience increased volatility due to regulatory compliance issues affecting similar companies.

Regional

Limited; primarily affects US-based biotech stocks with Nasdaq listings.

Global

negligible; specific to US biotech sector and Nasdaq-listed companies.

Counterpoint

What could challenge this read

The noncompliance may be a temporary technical issue, and the company could benefit from a strategic restructuring or capital raise, leading to potential upside.

Key entities

Regulatory Body
Nasdaq
The stock exchange requiring the minimum bid price.
Company
InMed Pharmaceuticals
Biotech firm facing noncompliance issues.

Read at source ← All news

JUL 22

$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min

JUL 22

$INMMedAI 8/10

InMed Shares Rise Pre-Market On Mentari's $200 Million Financing Ahead Of Merger

InMed Pharmaceuticals (INM) rose in pre-market after merger partner Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants. Mentari said the funds extend its runway to 2029 and support Phase 2a readouts for PACAP programs, including MT-002. The all-stock merger with InMed is expected to close in 2H 2026.

rttnews.com3 min

JUL 6

$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min

JUN 4

$INMMedAI 8/10

InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.

finanznachrichten.de4 min

AUG 9

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min